Evidence map›Paper›PMID 32255276›Full record

ReviewWiley interdisciplinary reviews. Nanomedicine and nanobiotechnology2020

Advances in engineering local drug delivery systems for cancer immunotherapy.

Peter Abdou, Zejun Wang, Qian Chen, Amanda Chan, Daojia R Zhou, Vivienne Gunadhi, Zhen Gu

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 69 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Mesoporous Silica Materials as an Emerging Tool for Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Peter AbdouDepartment of Bioengineering, University of California, Los Angeles, California, USA.ORCID 0000-0002-4195-3903
Zejun WangDepartment of Bioengineering, University of California, Los Angeles, California, USA.
Qian ChenInstitute of Functional Nano & Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials & Devices, Soochow University, 199 Ren'ai Road, Suzhou, China.
Amanda ChanDepartment of Bioengineering, University of California, Los Angeles, California, USA.
Daojia R ZhouDepartment of Bioengineering, University of California, Los Angeles, California, USA.
Vivienne GunadhiDepartment of Bioengineering, University of California, Los Angeles, California, USA.
Zhen GuDepartment of Bioengineering, University of California, Los Angeles, California, USA.ORCID 0000-0003-2947-4456
California NanoSystems Institute · USSoochow University · CNUniversity of California, Los Angeles · US

Funding

Platelets-Mediated Delivery of Checkpoint Inhibitors for Post-Surgical Cancer ImmunotherapyR01CA234343 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LI, SONG · 2019 to 2023
$2.0M
NCI NIH HHS R01 CA234343
6 · The paper itself

Abstract

Cancer immunotherapy aims to leverage the immune system to suppress the growth of tumors and to inhibit metastasis. The recent promising clinical outcomes associated with cancer immunotherapy have prompted research and development efforts towards enhancing the efficacy of immune checkpoint blockade, cancer vaccines, cytokine therapy, and adoptive T cell therapy. Advancements in biomaterials, nanomedicine, and micro-/nano-technology have facilitated the development of enhanced local delivery systems for cancer immunotherapy, which can enhance treatment efficacy while minimizing toxicity. Furthermore, locally administered cancer therapies that combine immunotherapy with chemotherapy, radiotherapy, or phototherapy have the potential to achieve synergistic antitumor effects. Herein, the latest studies on local delivery systems for cancer immunotherapy are surveyed, with an emphasis on the therapeutic benefits associated with the design of biomaterials and nanomedicines. This article is categorized under: Nanotechnology Approaches to Biology > Nanoscale Systems in Biology Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease.

Indexed as

Drug Delivery SystemsImmunotherapyNanomedicineAnimalsBiocompatible MaterialsHumansMiceNeoplasmsBiocompatible Materialsbiomaterialsdrug deliveryimmunotherapylocal deliverynanomedicine

Identifiers

PMID32255276
PMCPMC7725287
OpenAlexW3014122573

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.